New hope for deadly lymphoma combo: drug cocktail targets both cancer and immune chaos

NCT ID NCT07525466

Recruiting now Disease control Sponsor: Beijing Tongren Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests a new combination of drugs (MEPL-G) for people with a rare and aggressive lymphoma (NK/T-cell) that has triggered a life-threatening immune overreaction called HLH. The goal is to control both the cancer and the dangerous inflammation quickly. About 25 adults will receive this treatment to see if it improves survival and is safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTRANODAL NK/T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

extranodal nasal NK/T cell lymphoma hemophagocytic syndrome Lymphohistiocytosis, Hemophagocytic Lymphoma, Extranodal NK-T-Cell

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTRANODAL NK/T-CELL LYMPHOMA HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH)

Contacts and locations

Locations

Beijing Tongren Hospital, Capital Medical University
RECRUITING

Beijing, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.